<?xml version="1.0" encoding="UTF-8"?>
<p>In December 2019, a cluster of patients with primary pneumonia caused by a novel coronavirus was reported in Wuhan, China. The virus subsequently spread rapidly throughout the country and around the world.
 <xref rid="mja250577-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="mja250577-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="mja250577-bib-0003" ref-type="ref">3</xref> The novel coronavirus was later identified as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2); it exhibits 79.5% identity with the SARS‐CoV that caused the 2003 SARS epidemic.
 <xref rid="mja250577-bib-0004" ref-type="ref">4</xref> The disease caused by the new virus, coronavirus disease 2019 (COVID‐19), has clinical manifestations ranging from asymptomatic, mild pneumonia to serious acute respiratory distress syndrome (ARDS), septic shock, and multiple organ dysfunction syndrome (MODS).
 <xref rid="mja250577-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="mja250577-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="mja250577-bib-0007" ref-type="ref">7</xref> By 23 March 2020, 81 601 cases of COVID‐19 had been reported in mainland China, and the general mortality rate was 4.0%.
 <xref rid="mja250577-bib-0008" ref-type="ref">8</xref> The mortality rate among critically ill patients (61.5%) is similar to that previously reported for the Middle East respiratory syndrome (MERS), also caused by a coronavirus.
 <xref rid="mja250577-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="mja250577-bib-0009" ref-type="ref">9</xref> The mainstay of management of patients with COVID‐19 is supportive therapy, including fluid management, oxygen therapy, and mechanical ventilation.
 <xref rid="mja250577-bib-0010" ref-type="ref">10</xref>
</p>
